Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Boron compounds against human leukemic cells.

N Murmu1, S Mitra, M Das

  • 1Chittaranjan National Cancer Institute, Calcutta, India.

Journal of Experimental & Clinical Cancer Research : CR
|March 6, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurement of differential cross-sections of a single top quark produced in association with a <i>W</i> boson at <math> </math> with ATLAS.

The European physical journal. C, Particles and fields·2019
Same author

Erratum to: Measurement of the <i>W</i> boson polarisation in <math></math> events from <i>pp</i> collisions at <math> </math> in the lepton + jets channel with ATLAS.

The European physical journal. C, Particles and fields·2019
Same author

Search for CP Violation in D_{s}^{+}→K_{S}^{0}π^{+}, D^{+}→K_{S}^{0}K^{+}, and D^{+}→ϕπ^{+} Decays.

Physical review letters·2019
Same author

Search for Lepton-Universality Violation in B^{+}→K^{+}ℓ^{+}ℓ^{-} Decays.

Physical review letters·2019
Same author

Observation of B_{(s)}^{0}→J/ψpp[over ¯] Decays and Precision Measurements of the B_{(s)}^{0} Masses.

Physical review letters·2019
Same author

Search for the Production of a Long-Lived Neutral Particle Decaying within the ATLAS Hadronic Calorimeter in Association with a Z Boson from pp Collisions at sqrt[s]=13  TeV.

Physical review letters·2019
Same journal

Extracellular vesicle-mediated GALNT1/RPRD1A glycosylation axis drives immune escape and peritoneal metastasis in gastric cancer.

Journal of experimental & clinical cancer research : CR·2026
Same journal

NHE7-Driven endoplasmic reticulum stress signaling transmission promotes malignant progression of endometrial cancer via c-Fos/PRSS1/ERP27 axis.

Journal of experimental & clinical cancer research : CR·2026
Same journal

Correction: Nanovaccines with ferroptosis, necroptosis and STING-activation for synergistic immunotherapy.

Journal of experimental & clinical cancer research : CR·2026
Same journal

Adipocyte-rich microenvironment promotes TNBC progression through SIRT6-associated ACSL5 dysregulation and lipid storage-associated phenotypes.

Journal of experimental & clinical cancer research : CR·2026
Same journal

Correction: Copy number amplification-induced overexpression of lncRNA LOC101927668 facilitates colorectal cancer progression by recruiting hnRNPD to disrupt RBM47/p53/p21 signaling.

Journal of experimental & clinical cancer research : CR·2026
Same journal

Decoding glioblastoma evolution and heterogeneity through mechanistic modeling: implications for clinical translation.

Journal of experimental & clinical cancer research : CR·2026
See all related articles

Two novel boron compounds, dihydroxy(oxybiguanido) boron (III) hydrochloride monohydrate (HB) and guanidine biboric acid adduct (GB), demonstrated significant antitumor effects. These compounds effectively inhibited leukemic blast cell growth from chronic myeloid leukemia (CML) patients.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Chronic myeloid leukemia (CML) is a hematological malignancy characterized by uncontrolled proliferation of myeloid cells.
  • Development of novel therapeutic agents with improved efficacy and reduced toxicity is crucial for CML treatment.
  • Boron compounds have shown potential in various therapeutic applications, including cancer treatment.

Purpose of the Study:

  • To evaluate the antitumor effect of two new boron compounds: dihydroxy(oxybiguanido) boron (III) hydrochloride monohydrate (HB) and guanidine biboric acid adduct (GB).
  • To assess the impact of HB and GB on leukemic blast cells isolated from CML patients.
  • To investigate the molecular mechanisms underlying the apoptosis-inducing effects of HB and GB in immature blast cells.

Main Methods:

Related Experiment Videos

  • Isolation of leukemic blast cells from CML patients.
  • Assessment of cell growth inhibition and metabolic activity using MTT assay.
  • Measurement of 3H Thymidine incorporation to evaluate DNA synthesis inhibition.
  • Investigation of molecular mechanisms of apoptosis induction.

Main Results:

  • Both HB and GB significantly inhibited the growth of leukemic blast cells within 24 hours.
  • The IC50 values for GB and HB were determined to be 2 mg/ml.
  • MTT assay confirmed inhibition of metabolically active cells, and 3H Thymidine incorporation assays supported these findings.
  • Preliminary investigations into molecular mechanisms suggest HB and GB induce apoptosis.

Conclusions:

  • The novel boron compounds HB and GB exhibit significant antitumor activity against CML blast cells.
  • These compounds effectively inhibit cell proliferation and induce apoptosis, indicating their therapeutic potential.
  • Further research into the molecular pathways of apoptosis induced by HB and GB is warranted for CML treatment development.